Company
(symbol)#

Date
filed

Date
comm.

Shares/
units (M)

Price

Shares
out
(M)@

Lead, other
underwriters

Gross
(US$M)

Post-
offering
market
cap (M)%

INITIAL OFFERINGS TOTAL: $251.65M

Nabriva Therapeutics AG (Vienna; NBRV)1

6/23/15

9/21/15

9ADS

$10.25

1.98

Leerink Partners (co-lead); RBC Capital Markets (co-lead); Needham & Co.; Wedbush Pacgrow

$92.25

$2.02

Regenxbio Inc. (Rockville, Md.; RGNX)2

8/18/15

9/18/15

7.245S

$22

24.295

Morgan Stanley (co-lead); BofA Merrill Lynch (co-lead); Piper Jaffray (co-lead); Chardan Capital Markets

$159.4

$534.49


Number of IPOs in September: 2

Average value of September IPOs: $125.825M

Number of IPOs in 2015: 55

Total raised in IPOs in 2015: $5,358.76M

Average value of IPOs in 2015: $97.432M

FOLLOW-ON OFFERINGS TOTAL: $17,367.72M

Aquinox Pharmaceuticals Inc. (Vancouver, British Columbia; AQXP)

4/1/15

9/10/15

6.325S

$15.50

17.052

Needham & Co. (lead); Leerink Partners; Canaccord Genuity; Guggenheim Securities

$98

$264.31

Biogen Inc. (Cambridge, Mass.; BIOG)3

9/8/15

9/11/15

Senior notes

N/A

N/A

Goldman, Sachs & Co. (co-lead); Merrill Lynch, Pierce, Fenner & Smith Inc. (co-lead)

$6,000

N/A

Gilead Sciences Inc. (Foster City, Calif.; GILD)4

3/4/14

9/11/15

Senior notes

N/A

N/A

Merrill Lynch, Pierce, Fenner & Smith (co-lead); J.P. Morgan Securities (co-lead)

$10,000

N/A

Intra-Cellular Therapies Inc. (New York; ITCI)5

9/23/15

9/23/15

7.935

$43.50

42.975

Leerink Partners (co-lead); Cowen and Co. (co-lead); RBC Capital Markets (co-lead); Guggenheim Securities (co-lead); Ladenburg Thalmann & Co.; Suntrust Robinson Humphrey

$345

$1,869.41

La Jolla Pharmaceutical Co. (San Diego; LJPC)6

7/11/14

9/11/15

2.93S

$38

18.18

Jefferies (co-lead); Cowen and Co. (co-lead); Chardan Capital Markets; Lifesci Capital; Noble Life Science Partners

$111.4

$690.84

Mirati Therapeutics Inc. (San Diego; MRTX)7

9/24/14

9/17/15

2.25S

$45.00

18.598

Citigroup (co-lead); Barclays (co-lead); Leerink Partners (co-lead)

$101.3

$836.91

Seattle Genetics Inc. (Bothell, Wash.; SGEN)8

9/11/15

9/11/15

13.45S

$41

138.77

J.P. Morgan Securities (co-lead); Leerink Partners (co-lead); UBS Securities, Barclays Capital; RBC Capital Markets; Needham & Co.; William Blair

$552

$5,689.57

Trevena Inc. (King of Prussia, Pa.; TRVN)9

4/3/15

9/14/15

7.475S

$9.75

49.53

Jefferies (co-lead); Cowen and Co. (co-lead); Barclays Capital (co-lead); JMP Securities; Needham & Co.

$72.9

$482.92

Twi Pharmaceuticals Inc. (Taipei, Taiwan; Taiwan OTC: 4180.TWO)

9/18/15

9/18/15

14.4U

$6.05

N/A

Morgan Stanley

$87.12

N/A


Number of follow-on offerings in September: 9

Average value of September follow-ons: $1,929.75M

Number of follow-on offerings in 2015: 176

Total raised in follow-ons in 2015: $42,246.39M

Average value of follow-ons in 2015: $240.04M

Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics.

The 9M ADS represent 900,000 common shares. Nabriva's overallotment option: 1.35M ADS.

1 Includes Regenxbio's overallotment option: 945,000 shares.

2 Includes Aquinox's overallotment option: 825,000 shares.

3 Biogen sold $1.5B 2.9% senior notes due 2020, $1B 3.625% senior notes due 2022, $1.75B 4.05% senior notes due 2025, and $1.75B 5.2% senior notes due 2045.

4 Gilead priced $10B in senior unsecured notes in six tranches: $1B at 1.85% maturing in 2018, $2B at 2.55% maturing in 2020, $1B at 3.25% maturing in 2022, $2.75B at 3.65% maturing in 2026, $1B of 4.6% maturing in 2035 and $2.25B at 4.75% maturing in 2046.

5 Includes Intra-Cellular's overallotment option: 1.035M shares.

6 Includes La Jolla's overallotment option: 382,500 shares.

7 Mirati's overallotment option: 337,500 shares.

8 Includes Seattle Genetics' overallotment option: 1.75M shares.

9 Includes Trevena's overallotment option: 975,000 shares.